Dataset Information

Phosphoproteomics of endothelin signalling

ABSTRACT: Time resolved phosphorylation changes were measured the melanoma cell lines A2058 and UACC257. An endothelin B receptor knockout of UACC257 was processed in parallel. Protein abundance was also compared at the latest time point of the study (90 min) using DIA-SWATH

INSTRUMENT(S): TripleTOF 6600, LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Melanocyte

SUBMITTER: Alexander Schäfer

LAB HEAD: Ruedi Aebersold

PROVIDER: PXD012316 | Pride | 2019-10-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	A2058_iprophet.pep.xml	Pepxml
	OpenSWATH_output.tsv	Tabular
	Phospho_DDA_A2058_0min_Ctr_1.mzXML.mzXML	Mzxml
	Phospho_DDA_A2058_0min_Ctr_2.mzXML.mzXML	Mzxml
	Phospho_DDA_A2058_0min_Ctr_3.mzXML.mzXML	Mzxml

Items per page:

1 - 5 of 105

Publications

Elucidating essential kinases of endothelin signalling by logic modelling of phosphoproteomics data.

Schäfer Alexander A Gjerga Enio E Welford Richard Wd RW Renz Imke I Lehembre Francois F Groenen Peter Ma PM Saez-Rodriguez Julio J Aebersold Ruedi R Gstaiger Matthias M

Molecular systems biology 20190801 8

Endothelins (EDN) are peptide hormones that activate a GPCR signalling system and contribute to several diseases, including hypertension and cancer. Current knowledge about EDN signalling is fragmentary, and no systems level understanding is available. We investigated phosphoproteomic changes caused by endothelin B receptor (ENDRB) activation in the melanoma cell lines UACC257 and A2058 and built an integrated model of EDNRB signalling from the phosphoproteomics data. More than 5,000 unique phos ...[more]

PMID: 31464372

Similar Datasets

Project description:With the rapidly increasing availability of genomic data and ensuing identification of disease associated mutations, the determination of molecular mechanisms by which such mutations affect biochemical processes and phenotypes remains a major challenge. In this study we developed and applied a multilayered proteomic workflow to explore how genetic lesions modulate the modular proteome to alter functional phenotypes. Using this workflow we determined how expression of a panel of disease-associated mutations in the Dyrk2 protein kinase altered the composition, topology and activity of the multifunctional protein complex assembled around Dyrk2 and the phosphoproteomic state of the respective cells. We found that the selected cancer-related Dyrk2 mutations caused, to a differing extent, disassembly of the catalytic kinase core complex and caused disruption of interactions within the Dyrk2 core or with other cellular modules. This is exemplified by the nuclear pore associated Y-complex which we identified as new interactor of Dyrk2. We further found that the altered protein-protein interactions caused by the mutations are associated with topological changes and with changes in posttranslational modifications in the mutated kinase modules. Finally, we observed that the expression of each tested cancer-related mutation created a specific phosphoproteomic footprint including altered phosphorylation of known cancer-associated proteins, thus linking Dyrk2 mutations with cancer-related biochemical processes. Overall we developed an integrated, multilayered proteomic workflow to study how specific genomic mutations affect the modular proteome. Applying it to mutations in the Dyrk2 kinase we discover multiple mutation-specific, significant, pleiotropic and functionally relevant changes, highlighting the large plasticity of molecular responses to genomic lesions. The established workflow is generically applicable and will contribute to a better understanding of the molecular mechanisms that translate genomic alterations into (disease) phenotypes.